Benzinga

Benzinga Korea 한국

Benzinga

Benzinga Korea 한국

Benzinga

Benzinga Korea 한국
수요일, 8월 26

Kyverna Therapeutics Inc

KYTXNASDAQ
Trade with Public
Trade with Public
$8.84
0.607.28%
가까이에: Aug 25, 5:00 PM EST
$8.68
-0.16-1.8%
시간외: 6:05 PM EST
개요뉴스실적 전망이벤트목표가재무심리지분 현황비교옵션주식 보고서

Kyverna Therapeutics Financials

Kyverna Therapeutics (KYTX) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Kyverna Therapeutics Q2 EPS $(0.63) Beats $(0.68) Estimate

Kyverna Therapeutics (NASDAQ:KYTX) reported quarterly losses of $(0.63) per share which beat the analyst consensus estimate of $(0.68) by 7.35 percent. This is a 35.05 percent increase over losses of $(0.97) per share
Benzinga Newsdesk

PRO
Kyverna Therapeutics Q1 EPS $(0.66) Beats $(0.73) Estimate

Kyverna Therapeutics (NASDAQ:KYTX) reported quarterly losses of $(0.66) per share which beat the analyst consensus estimate of $(0.73) by 9.59 percent. This is a 35.92 percent increase over losses of $(1.03) per share
Benzinga Newsdesk

Kyverna Therapeutics (KYTX) Stock Surges 24% After Hours: Why Is It Moving?

Kyverna Therapeutics Inc. shares surged 24% after hours following positive registrational trial results for miv-cel in stiff person syndrome, showing significant improvement in walking speed.
Mohd Haider

PRO
Kyverna Therapeutics Q4 EPS $(0.80) Beats $(0.85) Estimate

Kyverna Therapeutics (NASDAQ:KYTX) reported quarterly losses of $(0.80) per share which beat the analyst consensus estimate of $(0.85) by 5.66 percent. This is a 8.11 percent decrease over losses of $(0.74) per share
Benzinga Newsdesk

Crude Oil Rises Over 1%; General Mills Earnings Top Views

Avi Kapoor

Dow Jumps 150 Points; Jabil Posts Upbeat Earnings

Avi Kapoor

데이터 및 API: Benzinga API · 주식 뉴스 API · 애널리스트 등급 API · 회사 로고 API

Benzinga

Benzinga Korea 한국

뉴스

파트너 / 기고자

벤징가 글로벌

© 2026 Benzinga | All Rights Reserved